Liz Lindquist is a partner in WilmerHale's Crisis Management and Strategic Response Practice who advises pharmaceutical, biotechnology, medical device and investor clients on market access, pricing and reimbursement, regulatory enforcement, government investigations and strategic transactions. She helps life sciences companies navigate complex commercial, regulatory and government-facing challenges, from product launch and market access to federal healthcare program participation, government contracting and litigation.

Liz advises clients throughout the product life cycle on issues involving drug pricing, reimbursement, coverage and commercialization. Her experience spans the Medicaid Drug Rebate Program, the 340B Drug Pricing Program, Medicare Parts B and D, the Veterans Affairs Federal Supply Schedule Program, TRICARE and state drug pricing regimes, among other federal and state healthcare programs. Her clients range from emerging biotechnology companies to global pharmaceutical and medical device manufacturers, private equity sponsors and investors.

A significant portion of Liz's practice focuses on pharmaceutical market access and commercialization. She counsels manufacturers on the pricing, reimbursement and contracting implications of product launch strategies, distribution models, patient support programs, value-based arrangements, specialty pharmacy relationships and other commercial initiatives. Clients regularly seek her guidance on evolving federal and state drug pricing policies, including implementation of the Inflation Reduction Act (IRA), the Medicare Drug Price Negotiation Program, inflation rebate requirements, state prescription drug affordability board (PDAB) reviews and related affordability initiatives. She is known for translating highly technical regulatory requirements into practical business strategies that support growth and long-term commercial objectives.

Emerging biotechnology and pharmaceutical companies, investors, private equity sponsors and established manufacturers regularly turn to Liz for strategic advice on launch readiness, compliance program development, licensing transactions, acquisitions and other growth-stage matters. She also advises buyers, sellers and portfolio companies on drug pricing, healthcare regulatory and government contracts issues arising in mergers and acquisitions, licensing arrangements, joint ventures and other strategic transactions.

For life sciences companies, Liz's work also spans the intersection of federal healthcare programs and government contracting. Her experience includes federal procurement requirements, Defense Production Act matters, domestic sourcing and Buy American obligations, BIOSECURE Act considerations, supply chain initiatives and other government-facing commercial and regulatory issues affecting product development and manufacturing operations.

In addition, Liz represents life sciences companies in government investigations, audits, enforcement actions, disputes and litigation involving drug pricing, reimbursement and federal healthcare program compliance. She regularly counsels clients in matters involving the Department of Justice, Centers for Medicare & Medicaid Services, Health Resources and Services Administration, HHS Office of Inspector General, VA Office of Inspector General and state attorneys general, including False Claims Act matters and other high-stakes regulatory and administrative proceedings.

Her counsel spans the full range of federal healthcare pricing and reimbursement programs as well as state drug pricing requirements, including transparency, affordability review, aggregate spend reporting, pharmacy benefit manager (PBM) regulation and related compliance obligations. She also develops and implements government advocacy, compliance and litigation strategies involving federal and state drug pricing initiatives and related administrative law challenges.

Prior to joining WilmerHale, Liz spent 15 years at two international law firms, where she was a member of the life sciences, healthcare regulation, FDA and government contracts practice groups.